A Single-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of GSK1070806 in the Treatment of Obese Subjects with T2DM
Phase of Trial: Phase II
Latest Information Update: 10 Sep 2015
At a glance
- Drugs GSK 1070806 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 24 Apr 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Aug 2013 Planned end date changed from 1 Jun 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.